Bacteremia caused by Acinetobacter junii at a medical center in Taiwan, 2000-2010.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
H-Y TsaiP-R Hsueh

Abstract

We investigated the clinical characteristics and outcomes of 43 patients with Acinetobacter junii bacteremia at a 2,500-bed tertiary care center in northern Taiwan. These organisms were confirmed to the species level by an array assay and 16S rRNA gene sequence analysis. The antimicrobial susceptibilities of the 43 A. junii isolates to 13 agents were determined using the agar dilution method. Susceptibility testing for tigecycline was determined using the broth microdilution method. Most of the patients were hospital-acquired (n = 36, 83.7 %) or healthcare facility-related infections (n = 6, 13.9 %), and 55.8 % had impaired immunity. Central venous access devices were present in 35 (81.4 %) patients; among the total of 43 patients with A. junii bacteremia, 8 patients were diagnosed as catheter-related bloodstream infection and 19 patients were diagnosed as catheter-associated bloodstream infection. Shock requiring inotropic agents occurred in 2 patients (4.6 %). Most patients developed bacteremia in general wards (n = 36, 83.7 %). The overall in-hospital mortality rate was low (7 %), despite the low rate of removal of central venous devices, low rate of holding usage of original central venous devices, and high rate of inapprop...Continue Reading

References

Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Apr 1, 1996·Clinical Microbiology Reviews·E Bergogne-Bérézin, K J Towner
Feb 24, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H SiauP C Woo
Jul 25, 2000·Diagnostic Microbiology and Infectious Disease·K PrashanthR Kanungo
Sep 15, 2001·European Journal of Internal Medicine·C ValeroM C. Fariñas
Jun 29, 2002·Journal of Clinical Microbiology·Hans-Jörg LindeNorbert Lehn
Nov 17, 2007·Nature Reviews. Microbiology·Lenie DijkshoornHarald Seifert
Jun 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Leonard A MermelDavid K Warren
Jun 17, 2009·Antimicrobial Agents and Chemotherapy·Mark D AdamsRobert A Bonomo
Oct 2, 2009·Journal of Clinical Microbiology·P J van den BroekL Dijkshoorn
Jul 22, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Wang-Huei ShengShan-Chwen Chang
Jul 8, 2011·Journal of Clinical Microbiology·Chih-Cheng LaiPo-Ren Hsueh
Sep 6, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Deborah TomlinsonLillian Sung
Sep 17, 2011·American Journal of Respiratory and Critical Care Medicine·Doo Ryeon ChungUNKNOWN Asian Network for Surveillance of Resistant Pathogens Study Group
Dec 14, 2011·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Kai-Chih ChangMing-Li Liou

❮ Previous
Next ❯

Citations

Aug 20, 2021·Microbiology Resource Announcements·Ana Sofía Escobedo-MuñozMiguel Ángel Cevallos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
M-R LeeP-R Hsueh
© 2021 Meta ULC. All rights reserved